Side-by-side financials for EDIT and RVMD. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EDIT | RVMD |
|---|---|---|
| Market cap | - | $32.71 B |
| US-listed rank | - | #439 |
| Revenue (latest FY) | $40.52M | $0.00 |
| Net income (latest FY) | -$160.06M | -$1.13B |
| Net margin | -395.0% | - |
| SEC filings | 693 | 782 |
In their latest fiscal years, Editas Medicine, Inc. reported $40.52M in revenue while Revolution Medicines, Inc. reported $0.00.
Full pages: Editas Medicine, Inc. and Revolution Medicines, Inc., or browse the full rankings.